Views
4 years ago

89 - L Carosella y col. - Noviembre 2014

  • Text
  • Scublinsky
  • Sagray
  • Guazzone
  • Carosella
  • Effects
  • Effects
  • Reactions
  • Events
  • Drugs
  • Neurologicos
  • Colaterales
  • Adversas
  • Adversos
  • Cardiovasculares
Efectos adversos neuropsiquiátricos de drogas de uso cardiológico

Dra. Lucia

Dra. Lucia Carosella, Dra. Analía Guazzone, Dr. Ezequiel Sagray, Dr. Darío Scublinsky la necesidad de mayores estudios clínicos para realizar conclusiones inequívocas al respecto (43, 44, 45, 46). Conclusión Es relevante el poder diferenciar los efectos colaterales del tratamiento farmacológico, con respecto a la patología neurológica producida por la misma enfermedad cardiovascular de base. Teniendo en cuenta que las cefaleas, la depresión y trastornos cognitivos, son los más frecuentemente descriptos en la literatura. Resaltamos que la mayoría de los efectos adversos tienen una secuencia temporal correlativa al síntoma; manifestándose en el inicio del tratamiento o aumento de la dosis, revirtiendo con la suspensión y reapareciendo con la readministración del fármaco. Es por todo lo antedicho, que consideramos imprescindible el conocimiento, por parte del médico tratante, de los efectos y los síntomas neurológicos y/o psiquiátricos que puede desarrollar el paciente bajo el tratamiento instaurado. Destacamos la necesidad de contar con estudios originales de mayor peso, en lo que respecta a la frecuencia y cualidad de los efectos adversos. El presente artículo expone la información disponible hasta el momento, siendo necesaria una constante actualización de los contenidos. Referencias bibliográficas 1. Olesen J.. Nitric oxide-related drug targets in headache. Neurotherapeutics. 2010;7(2):183-90. 2. Tvedskov JF IH, Olesen J, Tfelt-Hansen P. Nitroglycerin provocation in normal subjects is not a useful human migraine model? Cephalalgia. 2010;30(8):928-32. 3. Di Clemente L CG, Magis D, Gérardy PY, Fumal A, De Pasqua V, et al. Nitroglycerin sensitises in healthy subjects CNS structures involved in migraine pathophysiology: evidence from a study of nociceptive blink reflexes and visual evoked potentials. Pain. 2009;144(1-2):156-61. 4. Daugaard D TL, Iversen HK, Olesen J. Delayed migraine-like headache in healthy volunteers after a combination of acetazolamide and glyceryl trinitrate. Cephalalgia. 2009;29(12):1294-300. 5. Tfelt-Hansen PC T-HJ. Nitroglycerin headache and nitroglycerin-induced primary headaches from 1846 and onwards: a historical overview and an update. Headache. 2009;49(3):445-56. 6. Cho SH JM, Sim DS, Hong YJ, Park HW, Kim JH, et al. Diagnostic Value of Nitroglycerin-Induced Headache as a Negative Predictor of Coronary Atherosclerosis. Chonnam Med J. 2011;47(1):14–9. 7. Marsh N MA. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin Exp Pharmacol Physiol. 2000;27(4):313-9. 8. J. B. Migraine with aura after administration of sublingual nitroglycerin tablets. Headache. 2001;41(1):84-7. 9. Sicuteri F DBE, Poggioni M, Bonazzi A. Unmasking latent dysnociception in healthy subjects. Headache. 1987;27(4):180-5. 10. Thomsen LL KC, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol. 1994 1(1):73-80. 11. Afridi SK KH, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain. 2004;110(3):675-80. 12. A. B. Studies on nitroglycerin and histamine provoked cluster headache attacks. Cephalalgia. 1990;10(2):71-5. 13. Zaproudina N NM, Lipponen JA, Tarvainen MP, Karjalainen PA, Karhu J, et al. Nitroglycerin-induced changes in facial skin temperature: 'cold nose' as a predictor of headache? Clin Physiol Funct Imaging. 2013;33(6):409-17. 14. Brunton LL CB, Knollmann BC. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th Edition ed2011. 15. Huffman JC ST. Neuropsychiatric consequences of cardiovascular medications. Dialogues Clin Neurosci. 2007;9(1):29-45. 16. Guo S AM, Olesen J, Birk S. The effect of sodium nitroprusside on cerebral hemodynamics and headache in healthy subjects. Cephalalgia. 2013;33(5):301-7. 17. Huang X HL, Tang J, Zhang Y, Chen F, Wang D. Central nervous system toxicity of sodium nitroprusside in treatment of patients with aortic dissection. J Huazhong Univ Sci Technolog Med Sci. 2012;32(6):927-30. 18. Moffett BS PJ. Evaluation of sodium nitroprusside toxicity in pediatric cardiac surgical patients. Ann Pharmacother. 2008;42(11):1600-4. 19. Thomas C SL, Moffett BS. Sodium-nitroprussideinduced cyanide toxicity in pediatric patients. Expert Opin Drug Saf. 2009;8(5):599-602. 20. Friederich JA BJt. Sodium nitroprusside: twenty years and counting. Anesth Analg 1995 Jul;81(1):152- 62 21. EMA: European Medicines Agency. 22. Rathmann W HB, Roseman JM, Giani G. Cardiovascular drug prescriptions and risk of depression in diabetic patients. J Clin Epidemiol. 1999;52(11):1103-9. 23. Lindberg G BK, Ranstam J, Råstam L, Melander A. Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study. BMJ. 1998;316(7133):741-5. 24. Stelfox HT CG, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med. 1998;338(2):101-6. 25. Gasse C DL, Vasilakis C, Jick H. Risk of suicide among users of calcium channel blockers: population based, nested case-control study. BMJ. 2000;320(7244):1251. 26. Patten SB WJ, Love EJ. Case-control studies of cardiovascular medications as risk factors for clinically diagnosed depressive disorders in a hospitalized population. Can J Psychiatry. 1996;41(7):469-76. 27. Morimoto T GT, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10(4):499-509. 28. Callréus T AAU, Hallas J, Andersen M. Cardiovascular drugs and the risk of suicide: a nested case-control study. Eur J Clin Pharmacol. 2007;63(6):591-6. 29. Ferrario CM LP. Sexual Dysfunction in Patients With Hypertension: Implications for Therapy. J Clin Hypertens. 2002;4(6):424-32. 30. Paykel ES FR, Watson JP. Psychiatric side effects of antihypertensive drugs other than reserpine. J Clin Psychopharmacol. 1982;2(1):14-39. 31. Solomon S HE, Saravay SM, Bayer C, Ramsey P, Blum RS. Impairment of memory function by antihypertensive medication. Arch Gen Psychiatry. 1983;40(10):1109-12. 32. Johnson AG DR, Seldon WA. A functional psychosis precipitated by quinidine. Med J Aust. 1990;153(1):47-9. 33. Deleu D SE. Acute psychosis as idiosyncratic reaction to quinidine: report of two cases. Br Med J (Clin Res Ed). 1987;294(6578):1001-2. 34. Bizjak ED NPJ, Brody EA, Galloway JM. Procainamide-induced psychosis: a case report and review of the literature. Ann Pharmacother. 1999;33(9):948-51. 35. L H. Procainamide-induced psychosis. Crit Care Nurse. 1993;13(6):70-2. 36. Schubert DS GL, Hershey LA. Psychosis induced by sustained-release procainamide. Can Med Assoc J. 1984;131(10):1188-90. 37. FDA, Food And Drug Administration. Actualización de vigilancia de estatinas del 19/03/2014. 38. Antiarrhythmic drugs and polyneuropathy. The Collaborative Group for the Study of Polyneuropathy. J Neurol Neurosurg Psychiatry. 1994;57(3):340-3. 39. Furosemida. Prospecto aprobado por la FDA. Revisión de Septiembre de 2010. 40. DA S. Loop diuretic therapy, thiamine balance, and heart failure. Congest Heart Fail. 2007;13(4):244-7. 41. Miguel E GR, Antón A, Montiel JA, Mayos M. Acute confusional syndrome associated with obstructive sleep apnea aggravated by acidosis secondary to oral acetazolamide treatment. Arch Bronconeumol. 2004;40(6):283-6. 42. CN I. The contrast between digitalis intoxication in children and adults. J Natl Med Assoc. 1970;62(1):38- 41. 43. K. Richardson, M. Schoen, B. French, et al., “Statins and cognitive function: a systematic review,” Annals of Internal Medicine, vol. 159, no. 10, pp. 688–697, 2013. 44. Corley J, Starr JM, Deary IJ. "Serum cholesterol and cognitive functions: the Lothian Birth Cohort 1936." Int Psychogeriatric. 2014 Jul 15:1-15. 45. Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. " Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects." Mayo Clin Proc. 2013 Nov;88(11):1213-21. 46. Steenland K, Zhao L, Goldstein FC, Leyey AI. "Statins and cognitive decine in older adults with normal cognition or mild cognitive impairment." J Am Geriatr Soc. 2013 Sep;61(9): 1449-55. 28 // EDITORIAL SCIENS

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015